What is Anacor Pharmaceuticals Retained Earnings?
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Anacor Pharmaceuticals's retained earnings for the quarter that ended in Mar. 2016 was $-294.99 Mil.
Anacor Pharmaceuticals's quarterly retained earnings
declined
from Sep. 2015 ($-259.93 Mil) to Dec. 2015 ($-278.84 Mil) and
declined
from Dec. 2015 ($-278.84 Mil) to Mar. 2016 ($-294.99 Mil).
Anacor Pharmaceuticals's annual retained earnings
declined
from Dec. 2013 ($-130.45 Mil) to Dec. 2014 ($-217.59 Mil) and
declined
from Dec. 2014 ($-217.59 Mil) to Dec. 2015 ($-278.84 Mil).
Anacor Pharmaceuticals Retained Earnings Calculation
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Anacor Pharmaceuticals (NAS:ANAC) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Anacor Pharmaceuticals (Anacor Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
Anacor Pharmaceuticals Inc was incorporated in Delaware in December 2000 and began business operations in March 2002. It is a biopharmaceutical company engaged in discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It has discovered, synthesized and developed eight molecules that are currently in development. The Company's main product candidates include two topically administered dermatologic compounds, tavaborole (formerly referred to as AN2690) and AN2728. Tavaborole is a topical treatment for onychomycosis, a fungal infection of the nail and nail bed. AN2728 is its main topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory skin diseases that affect millions of people. In addition, the Company has three other wholly-owned clinical product candidates; AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK '052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC (GSK). It has also discovered three other compounds that it has out-licensed for further development; one is licensed to Eli Lilly and Company (Lilly), for the treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative (DNDi), for human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for tuberculosis (TB). As of February 1, 2014, the company was the owner of record, either solely or with a collaborator, of 23 issued U.S. patents. The Company and its third-party manufacturers are subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of its products to assess its compliance with applicable regulations.
Executives
| Keith R Leonard |
director |
ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
| William Jl Rieflin |
director |
NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
| Anders D Hove |
director |
30 ROCKEFELLER PLAZA, SUITE 5508, NEW YORK NY 10112 |
| Lucy Shapiro |
director |
10210 GENETIC CENTER COURT, SAN DIEGO CA 92121 |
| Graeme Bell |
officer: Executive VP and CFO |
1324 WAVERLY ROAD, GLADWYNE PA 19035 |
| Ryan T Sullivan |
officer: EVP and General Counsel |
C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07855 |
| Wendall Wierenga |
director |
12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
| Paul L Berns |
director, officer: President and CEO |
11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020 |
| Mark Leschly |
director |
RHO CAPITAL PARTNERS, INC., 152 W 57TH ST 23RD FL, NEW YORK NY 10019 |
| Geoffrey M. Parker |
officer: Executive Vice President & CFO |
15 RIORDAN PLACE, MENLO PARK CA 94025 |
| Paul H Klingenstein |
director |
428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301 |
| David P Perry |
director, officer: President and CEO |
1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303 |
| Rho Management Ventures Iv Llc |
10 percent owner |
124 DUNE RD, QUOGUE NY 11959 |
| Rho Ventures Iv Qp Lp |
10 percent owner |
124 DUNE RD, QUOGUE NY 11959 |
| Rho Ventures Iv Lp |
10 percent owner |
124 DUNE ROAD, QUOGUE NY 11959 |
Anacor Pharmaceuticals (Anacor Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANAC has been successfully added to your 